14432-11-2

Basic information

• Product Name: 3H-Imidazo[4,5-b]pyridine, 7-nitro-, 4-oxide
• Synonyms: 3H-Imidazo[4,5-b]pyridine, 7-nitro-, 4-oxide;7-nitro-1H-iMidazo[4,5-b]pyridine 4-oxide;7-Nitro-3H-iMidazo[4,5-b]pyridine 4-oxide;4-hydroxy-7-nitroimidazo[4,5-b]pyridine
• CAS NO: 14432-11-2
• Molecular Formula: C₆H₄N₄O₃
• Molecular Weight: 180.12
• Mol File: 14432-11-2.mol
• Article Data: 7

Chemical Properties

• Melting Point: 289 °C (decomp)
• Boiling Point: 602.4±58.0 °C(Predicted)
• Appearance: /
• Density: 1.89±0.1 g/cm3(Predicted)
• PKA: 3.94±0.40(Predicted)
• CAS DataBase Reference: 3H-Imidazo[4,5-b]pyridine, 7-nitro-, 4-oxide(CAS DataBase Reference)
• NIST Chemistry Reference: 3H-Imidazo[4,5-b]pyridine, 7-nitro-, 4-oxide(14432-11-2)
• EPA Substance Registry System: 3H-Imidazo[4,5-b]pyridine, 7-nitro-, 4-oxide(14432-11-2)

Safety Data

• Hazardous Substances Data: 14432-11-2(Hazardous Substances Data)

Usage

General Description

3H-Imidazo[4,5-b]pyridine, 7-nitro-, 4-oxide is a chemical compound that belongs to the class of imidazopyridines. It is a nitro derivative and contains an oxygen atom in the 4-position of the molecule. 3H-Imidazo[4,5-b]pyridine, 7-nitro-, 4-oxide has potential biological and pharmacological activities and may be used in the synthesis of pharmaceuticals. It is important to handle this chemical with caution due to its potential reactivity and toxicity. Further research and analysis are needed to fully understand the properties and potential applications of 3H-Imidazo[4,5-b]pyridine, 7-nitro-, 4-oxide.

Upstream product

• 6863-46-3 Imidazo<4,5-b>pyridine 4-Oxide 
• 273-21-2 1H-Imidazo[4,5-b]pyridine 
• 452-58-4 2,3-Diaminopyridine 
• 273-21-2 3H-imidazo[4,5-b]pyridine 
• 6863-46-3 3H-Imidazo<4,5-b>pyridine 4-N-oxide 

Downstream Products

• 500896-84-4 2,6-dichloro-9-benzyl-1-deazapurine 
• 929533-19-7 3-benzyl-5,7-diphenyl-3H-imidazo[4,5-b]pyridine 
• 1445877-12-2 5,7-dichloro-3-(2-methyl-3-(trifluoromethyl)benzyl)-3H-imidazo[4,5-b]pyridine 
• 1445877-04-2 3-(2-methyl-3-(trifluoromethyl)benzyl)-5-morpholino-3H-imidazo[4,5-b]pyridin-7-ol 
• 566194-68-1 5-chloro-7-(4-nitrobenzylsulfanyl)-3-(2',3',5'-tri-O-acetyl-β-D-ribofuranosyl)-3H-imidazo[4,5-b]pyridine 
• 566194-66-9 5-chloro-7-(benzylsulfanyl)-3-(2',3',5'-tri-O-acetyl-β-D-ribofuranosyl)-3H-imidazo[4,5-b]pyridine 
• 24485-01-6 5,7-dichloro-3H-imidazo<4,5-b>pyrimidine 
• 6703-44-2 1-Deazaadenine 
• 77712-93-7 7-Amino-3H-imidazo<4,5-b>pyridine 4-N-Oxide 

Relevant articles and documents

New (1-deaza)purine derivatives via efficient C-2 nitration of the (1-deaza)purine ring

Nitration of substituted (1-deaza)purines using a mixture of tetrabutylammonium nitrate (TBAN) and trifluoracetic acid anhydride (TFAA) was applied to prepare nitrosubstituted (1-deaza)purines at low temperature. The nitro group influences the system twofold: 1) it activates other substituents towards nucleophilic aromatic substitution and 2) it can be substituted itself leading to a variety of di-substituted (1-deaza)purines, also via solid phase syntheses. Several of the molecules obtained were studied for their antiprotozoal activity and for interactions with the different human adenosine receptors.

Fluorescing Isofunctional Ribonucleosides: Assessing Adenosine Deaminase Activity and Inhibition

The enzymatic conversion of isothiazolo[4,3-d]pyrimidine-based adenosine (tzA) and 2-aminoadenosine (tz2-AA) analogues to the corresponding isothiazolo[4,3-d]pyrimidine-based inosine (tzI) and guanosine (tzG) derivatives is evaluated and compared to the conversion of native adenosine to inosine. Henri–Michaelis–Menten analyses provides the foundation for a high-throughput screening assay, and the efficacy of the assay is showcased by fluorescence-based analysis of tzA conversion to tzI in the presence of known and newly synthesized inhibitors.

IMIDAZOPYRIDINE DERIVATIVES AS PI3 KINASE INHIBITORS

This invention relates to the use of imidizopyridine derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3' OH kinase family (hereinafter PI3 kinases), suitably, PI3Kα, PI3Kδ, PI3Kβ, and/or PI3Kγ. Suitably, the present invention relates to the use of imidizopyridines in the treatment of one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries. More suitably, the present invention relates to PI3Kβ selective imidizopyridine compounds for treating cancer.

2,6,8-Trisubstituted 1-deazapurines as adenosine receptor antagonists

In this study we developed a refined pharmacophore model for antagonists of the human adenosine A1 receptor, based on features of known pyrimidine and purine derivatives. The adoption of these updated criteria assisted us in synthesizing a series of 1-deazapurines with consistently high affinity as inverse agonists for the adenosine A1 receptor. These 1-deazapurines (otherwise known as 3H-imidazo[4,5-b]pyridines) were substituted at their 2- and 6-positions, yielding a series with five of the derivatives displaying Ki values in the subnanomolar range. The most potent of these, compound 10 (LUF 5978), displayed an affinity of 0.55 nM at the human adenosine A1 receptor with > 300-fold and 45-fold selectivity toward A2A and A3 receptors, respectively. Compound 14 (LUF 5981, Ki = 0.90 nM) appeared to have the best overall selectivity with respect to adenosine A2A (> 200-fold) and A 3 (700-fold) receptors.